|Articles|October 20, 2021

Hospitals That Use More Antibiotics May Have More C Difficile Infections

Author(s)Nina Cosdon

Higher use of 7 major antibiotics in hospitals is corelated with higher rates of Clostridioides difficile infection.

Clostridioides difficile (C. diff) incidence has recently decreased, but it is still classified as an urgent health threat by the Centers got Disease Control and Prevention (CDC).

These decreases are especially significant in cases of hospital-onset C. diff infection (HO-CDI). HO-CDI has dropped despite national rates of antibiotic use have remained consistent. A study published in Infection Control and Hospital Epidemiology endeavored to use recent data to see if there was any link between hospital-level antibiotic use and HO-CDI rates.

Investigators surveyed adult hospital discharge and inpatient charge records of antibiotic use, CDI tests, and treatment from acute-care hospitals (ACHs). The data was collected from the Premier Healthcare Database and was from January 1, 2012-December 31, 2018. According to the study, “A case of HO-CDI was defined as a hospital discharge with an International Classification of Diseases (ICD) code specifying enterocolitis due to Clostridioides difficile (ICD-9 008.45 or ICD-10 A04.7, A04.71, or A04.72) in any secondary diagnostic position and inpatient treatment with metronidazole (parenteral or oral), fidaxomicin, or vancomycin (oral) initiated on hospital day 3 or later after admission.”

The investigators calculated monthly rates of HO-CDI per 10000 patient days (PD), and measured hospital antibiotic usage by days of therapy (DOT) per 1000 PD. This data was examined by monthly rates of antibiotic use according to 7 antibiotic classes: fluoroquinolones, third-generation and fourth-generation cephalosporins (cephalosporins), piperacillin-tazobactam, carbapenems, β-lactam/β-lactamase inhibitor combination (excluding piperacillin-tazobactam), clindamycin, and penicillin.

The cross-sectional relationships between rates of HO-CDI and antibiotic use were examined through multivariable generalized estimating equation models (GEE). All GEE models were adjusted for various factors. Investigators assessed temporal trends in HO-CDI rates using GEE models adjusted for seasonality.

Results included 921 hospitals, among which the average HO-CDI rate was 6.7 per 10000 patient days. In the cross-sectional multivariable analysis, antibiotic use was significantly associated with facility-level rates of HO-CDI. Investigators found a consistent trend of a 2.8% increase in HO-CDI rate for every 50 DOT per 1000 PD increase in antibiotic usage.

The analysis found statistically significant positive associations between total, third-generation, and fourth-generation cephalosporin, fluoroquinolone, carbapenem, and piperacillin-tazobactam use and HO-CDI rates. Specifically, decreases in the use of these antibiotics correlated with decreases in HO-CDI. The greatest HO-CDI rate decreases occurred in a subset of ACHs that decreased total antibiotic usage by 30%, results that aligned with previous studies


Related to this article

Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.